ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,008,637 | -45.2% | 50,281 | -23.0% | 0.00% | -100.0% |
| Q2 2023 | $1,842,141 | +129.1% | 65,301 | +39.7% | 0.00% | – |
| Q1 2023 | $804,221 | +1173.3% | 46,757 | +1391.0% | 0.00% | – |
| Q4 2022 | $63,160 | -48.2% | 3,136 | -44.7% | 0.00% | – |
| Q3 2022 | $122,000 | -90.8% | 5,669 | -88.0% | 0.00% | – |
| Q2 2022 | $1,323,000 | -77.7% | 47,083 | -63.3% | 0.00% | -100.0% |
| Q1 2022 | $5,924,000 | -45.8% | 128,418 | -1.2% | 0.00% | -33.3% |
| Q4 2021 | $10,925,000 | -66.9% | 129,980 | -73.8% | 0.00% | -57.1% |
| Q3 2021 | $33,035,000 | +22.4% | 495,731 | -2.3% | 0.01% | +16.7% |
| Q2 2021 | $26,983,000 | +16057.5% | 507,196 | +13050.0% | 0.01% | – |
| Q1 2021 | $167,000 | -80.9% | 3,857 | -77.1% | 0.00% | – |
| Q4 2020 | $876,000 | +217.4% | 16,865 | +99.6% | 0.00% | – |
| Q3 2020 | $276,000 | +9.5% | 8,450 | +61.1% | 0.00% | – |
| Q2 2020 | $252,000 | – | 5,245 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |